ライフサイエンスコーパス: pulmonary infiltrate

1 n a child with sickle cell disease and a new pulmonary infiltrate.

2 lanoma presented with the chief complaint of pulmonary infiltrates.

3 noninfectious complications that manifest as pulmonary infiltrates.

4 and an increase in macrophage percentage in pulmonary infiltrates.

5 y-function tests or resolution or absence of pulmonary infiltrates.

6 ICU over a 3-year period, 44% (40) developed pulmonary infiltrates.

7 tors of pneumonia versus other etiologies of pulmonary infiltrates.

8 alter CTL generation or to affect Ad-induced pulmonary infiltrates.

9 but, of 6 patients at level III, 1 developed pulmonary infiltrates, 1 developed hypotension (both res

10 patient presenting with fever, hypoxia, and pulmonary infiltrates after OLT for hepatitis C.

11 woman presented to the hospital with nodular pulmonary infiltrates and acute renal failure.

12 ing a mortality rate of 50% in subjects with pulmonary infiltrates and an overall mortality of 33.3%.

13 but reversible early graft dysfunction with pulmonary infiltrates and hypoxemia, attributed to ische

14 50%) developed severe graft dysfunction with pulmonary infiltrates and hypoxemia.

15 r infusion, they became critically ill, with pulmonary infiltrates and lung injury, renal failure, an

16 ce of severe graft dysfunction manifested as pulmonary infiltrates and severe hypoxemia with onset in

17 pulmonary tuberculosis, one having fever and pulmonary infiltrates and the other having subclinical d

18 ction in lung with LRTD symptoms without new pulmonary infiltrates), and proven (PIV detection in lun

19 lmonary edema, refractory hypoxemia, diffuse pulmonary infiltrates, and altered lung compliance.

20 rent episodes of wheezing, mucus production, pulmonary infiltrates, and elevated levels of serum IgE.

21 corticosteroids with resolution of hypoxia, pulmonary infiltrates, and glomerulonephritis.

22 I, and they presented more often with shock, pulmonary infiltrates, and renal dysfunction (p < 0.0001

23 ear and take an unusual course, even when no pulmonary infiltrates appear.

24 In 4 neonates, pulmonary infiltrates at presentation were bilateral and

25 olonization, IgE and IgG anti-Af antibodies, pulmonary infiltrates, bronchiectasis, and pulmonary fib

26 dentifying pneumonia as a potential cause of pulmonary infiltrates, but for the likely etiology of th

27 Six subjects had pulmonary infiltrates, but in 3 cases there were no abno

28 Development of pulmonary infiltrates, cardiomyopathy, and eosinophilia

29 Clinical presentations included asymptomatic pulmonary infiltrates, chronic cough, and shortness of b

30 primed for a strong cytolytic response and a pulmonary infiltrate consisting primarily of mononuclear

31 .v. yeast wall glucan developed consolidated pulmonary infiltrates consisting predominantly of macrop

32 of organism-mediated pulmonary injury and of pulmonary infiltrates detected by thoracic computed tomo

33 mbocytopenia, hypersensitivity reaction, and pulmonary infiltrates (fatal in two patients).

34 eumonia, accurately identified patients with pulmonary infiltrates for whom monotherapy with a short

35 sis in 73 nonimmunocompromised patients with pulmonary infiltrates for whom the test was ordered.

36 hest syndrome (ACS) is the presence of a new pulmonary infiltrate in combination with fever or respir

37 Chest radiographs showed pulmonary infiltrates in all patients.

38 alent, but unnecessary in most patients with pulmonary infiltrates in the ICU.

39 utive liver transplant recipients developing pulmonary infiltrates in the ICU.

40 therapy in liver transplant recipients with pulmonary infiltrates in the intensive care unit (ICU).

41 ious pulmonary complications that present as pulmonary infiltrates include idiopathic pneumonia syndr

42 ficiency virus-specific cytotoxic T cells in pulmonary infiltrates, increased survival time, and a re

43 Inappropriate antibiotic use for pulmonary infiltrates is common in the intensive care un

44 had evidence of mediastinitis and extensive pulmonary infiltrates late in their course of illness.

45 esent with hypoxemic respiratory failure and pulmonary infiltrates, meeting criteria for acute respir

46 -) animals had eosinophilic and neutrophilic pulmonary infiltrates not present in wild-type or IFN-ga

47 lized for CAP; 5.4% had PO-CAP, defined as a pulmonary infiltrate occurring distal to an obstructed b

48 lvement (RD, 25.5%; 95% CI, 13.9% to 37.0%), pulmonary infiltrates (odds ratio, 4.9; 95% CI, 1.5-16.2

49 I, 1.2-55.2]; p = 0.032), and more extensive pulmonary infiltrates (odds ratio, 9.7 [95% CI, 3.6-25.9

50 revealed the presence of eosinophils in the pulmonary infiltrate of the vaccinated children.

51 Pulmonary infiltrates of cytotoxic lymphocytes, the lack

52 s syndrome presents as hypoxia and bilateral pulmonary infiltrates on chest imaging in the absence of

53 of > 0.5 while intubated, bilateral diffuse pulmonary infiltrates on chest radiograph, and exclusion

54 CI, 1.6 to 3.7), and multilobar radiographic pulmonary infiltrate (OR = 3.1; 95% CI, 1.9 to 5.1).

55 unexplained fever, weight gain, dyspnea with pulmonary infiltrates, pleuropericardial effusion, hypot

56 ack male with sickle cell disease, bilateral pulmonary infiltrates, refractory hypoxemia, and unstabl

57 Pulmonary infiltrates seen on chest radiographs correspo

58 Pulmonary infiltrating T lymphocytes may express integri

59 hypoxemic respiratory failure with bilateral pulmonary infiltrates that are not attributed to left at

60 considered in the differential diagnosis of pulmonary infiltrates that occur acutely after bone marr

61 who developed fever, hypoxia, and bilateral pulmonary infiltrates two and a half years after orthoto

62 Pugin score >6 in patients with pulmonary infiltrates warrants antimicrobial therapy.

63 Overall mortality in patients with pulmonary infiltrates was 28% (11 of 40); pneumonia as e

64 who were undergoing bronchoscopy because of pulmonary infiltrates was analyzed.

65 etection in upper respiratory tract with new pulmonary infiltrates with/without LRTD symptoms), proba

66 , and proven (PIV detection in lung with new pulmonary infiltrates with/without LRTD symptoms).